

Freedom of Information Request: Our Reference CTHB_186_17

You asked:

1. How many adult severe asthma patients have been seen via both in-patient visits and outpatient clinics in the last 3 months?
2. How many adult severe asthma patients have you treated with a biologic in the last 3 months?
3. Of these patients treated, can you provide which drugs they were treated with, as follows:
 - Omalizumab (Xolair)
 - Mepolizumab (Nucala)
 - Reslizumab (Cinqaero)

Our response:

Within the Health Board, we use J46.X "status asthmaticus" as the code to identify 'severe asthma'. All three drugs listed above are coded as X96.2.

Therefore, please see the table below which provides the numbers of inpatient episodes along with the drug used.

Inpatient Episodes With a Diagnosis of Status Asthmaticus (ICD10: J46*)

Inpatient Episodes	Primary	Secondary
Diagnosis of Status asthmaticus	9	0
OPCS4 Code: X962	0	0

We do not currently record a diagnosis at outpatient appointments and therefore we are unable to provide this element of your request.